Cytosorbents Corp

CTSONASDAQ · USD
4.87USD+4.52 (-9.32%)
312

Cytosorbents Corp (CTSO) Historical Volatility

CTSO's 30 day historical volatility is 99.87%, in the 81st percentile of readings over the past year. This is a high percentile, meaning Cytosorbents Corp shares have swung far more than usual. CTSO's 30 day implied volatility sits at 11,588.48%, with an IV Rank of 100.00%, leaving IV 11,488.61 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.

Read more

Tracking CTSO historical volatility helps you see how much Cytosorbents Corp's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, CTSO's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor CTSO 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. CTSO's 30 day historical volatility, or CTSO HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing CTSO's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.

Historical Volatility

HV Percentile
81stHV Percentile
High

Historical movement is elevated versus the past year. The stock has been unusually active.

Historical Volatility (30d)99.87%

HV Percentile81st

Implied Volatility (30d)11588.48%

IV Rank100.00%

IV Minus HV+11,488.61%

As of Nov 13, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 13, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →